Approval · Notice of Compliance 33612 · 2024
AG-SUMATRIPTAN: Notice of Compliance 33612
Issued July 11, 2024
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 33612
- Date
- July 11, 2024
- Company
- Angita Pharma Inc.Boucherville, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Administrative: Licensing Agreement between two manufacturers
- Canadian reference product
- APO-SUMATRIPTAN (Apotex Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AG-SUMATRIPTAN | 02549689 | Approved |
| AG-SUMATRIPTAN | 02549697 | Approved |
| AG-SUMATRIPTAN | 02549700 | Approved |
Medicinal ingredients
- SUMATRIPTAN 25 MG per TAB
- SUMATRIPTAN 50 MG per TAB
- SUMATRIPTAN 100 MG per TAB